No Data
No Data
Risks To Shareholder Returns Are Elevated At These Prices For Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707)
Zhongtai: The implementation of the tenth batch of centralized procurement is expected to accelerate the clearance of generic drugs. Commercial insurance is an important incremental logic in the pharmaceutical Sector.
It is recommended to keep a close eye on the progress and implementation of commercial insurance, as improvements in the payment sector are expected to bring about a significant market trend in the Pharmaceutical Sector, with opportunities for recovery and reversal in hospital pharmaceuticals, diagnostics, and Medical Devices.
Recent 4.8% Pullback Would Hurt Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) Insiders
Nanjing King-Friend Biochemical Pharmaceutical Gets US FDA Registration Approval for Vitamin B12 Injection
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): Vitamins B12 injection has obtained the pharmaceutical registration approval from the USA FDA.
On November 18, Gelonghui reported that Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that the company recently received the approval letter from the USA Food and Drug Administration (referred to as "USA FDA") for Vitamin B12 Injection, 1,000 mcg/mL, 10,000 mcg/10 mL (1,000 mcg/mL), 30,000 mcg/30 mL (1,000 mcg/mL) (ANDA No.: 214316).
Are Investors Undervaluing Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) By 44%?
No Data